Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Veerle F Surmont

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Expert Review of Anticancer Therapy|October 18, 2011
Raltitrexed in mesotheliomaVeerle F Surmont, Jan P van Meerbeeck
Critical Reviews in Oncology/Hematology|May 15, 2010
Malignant pleural mesothelioma: the standard of care and challenges for future managementJan P van Meerbeeck, Arnaud Scherpereel, Veerle F Surmont, et al.
Expert Review of Anticancer Therapy|April 21, 2011
Malignant pleural mesothelioma: when is radiation therapy indicated?Eric R E van Thiel, Veerle F Surmont, Jan P van Meerbeeck
Frontiers in Oncology|June 6, 2012
Investigational approaches for mesotheliomaVeerle F Surmont, Eric R E van Thiel, Karim Vermaelen, et al.
European Journal of Cancer (Oxford, England : 1990)|December 31, 2015
Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a 'chemosensitive' relapse: A single-arm phase II study (EORTC-08061)Fatma Abdelraouf, Egbert Smit, Baktiar Hasan, et al.
Lung Cancer (Amsterdam, Netherlands)|April 17, 2002
Unexpected response of a pulmonary blastoma on radiotherapy: a case report and review of the literatureVeerle F Surmont, Rob J van Klaveren, Peter J C M Nowak, et al.
Cancers|July 9, 2022
External Validation of a Breath-Based Prediction Model for Malignant Pleural MesotheliomaEline Janssens, Eline Schillebeeckx, Kathleen Zwijsen, et al.
Journal of Breath Research|September 8, 2023
Determining the clinical utility of a breath test for screening an asbestos-exposed population for pleural mesothelioma: baseline resultsKathleen Zwijsen, Eline Schillebeeckx, Eline Janssens, et al.
European Journal of Cancer (Oxford, England : 1990)|August 2, 2011
A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03)Rabab M Gaafar, Veerle F Surmont, Giorgio V Scagliotti, et al.
Frontiers in Oncology|June 21, 2018
Invasive Aspergillosis Mimicking Metastatic Lung CancerMichiel J E G W Vanfleteren, Anne-Marie C Dingemans, Veerle F Surmont, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Expert Review of Anticancer Therapy|October 18, 2011
Raltitrexed in mesotheliomaVeerle F Surmont, Jan P van Meerbeeck
Critical Reviews in Oncology/Hematology|May 15, 2010
Malignant pleural mesothelioma: the standard of care and challenges for future managementJan P van Meerbeeck, Arnaud Scherpereel, Veerle F Surmont, et al.
Expert Review of Anticancer Therapy|April 21, 2011
Malignant pleural mesothelioma: when is radiation therapy indicated?Eric R E van Thiel, Veerle F Surmont, Jan P van Meerbeeck
Frontiers in Oncology|June 6, 2012
Investigational approaches for mesotheliomaVeerle F Surmont, Eric R E van Thiel, Karim Vermaelen, et al.
European Journal of Cancer (Oxford, England : 1990)|December 31, 2015
Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a 'chemosensitive' relapse: A single-arm phase II study (EORTC-08061)Fatma Abdelraouf, Egbert Smit, Baktiar Hasan, et al.
Lung Cancer (Amsterdam, Netherlands)|April 17, 2002
Unexpected response of a pulmonary blastoma on radiotherapy: a case report and review of the literatureVeerle F Surmont, Rob J van Klaveren, Peter J C M Nowak, et al.
Cancers|July 9, 2022
External Validation of a Breath-Based Prediction Model for Malignant Pleural MesotheliomaEline Janssens, Eline Schillebeeckx, Kathleen Zwijsen, et al.
Journal of Breath Research|September 8, 2023
Determining the clinical utility of a breath test for screening an asbestos-exposed population for pleural mesothelioma: baseline resultsKathleen Zwijsen, Eline Schillebeeckx, Eline Janssens, et al.
European Journal of Cancer (Oxford, England : 1990)|August 2, 2011
A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03)Rabab M Gaafar, Veerle F Surmont, Giorgio V Scagliotti, et al.
Frontiers in Oncology|June 21, 2018
Invasive Aspergillosis Mimicking Metastatic Lung CancerMichiel J E G W Vanfleteren, Anne-Marie C Dingemans, Veerle F Surmont, et al.
Pageof 2